When a drug suppresses appetite this aggressively, people often stop building the habits that sustain health long term
Interest in this possibility was rekindled by John Dupr, a Canadian endocrinologist at St Thomas' Hospital in London
Weeks 20 through 48 (maintenance): check-ins every 8 to 12 weeks
Over 52 weeks, resolution of MASH without worsening of fibrosis was achieved in 10% of the placebo group, 44% of the tirzepatide 5 mg group, 56% of the 10 mg group, and 62% of the 15 mg group
Her work has appeared in publications like Mens Health , Womens Health , AARP The Magazine , EatingWell and Prevention , and she has also led strategic communications for a top engineering college and a global oncology company.
17 , e13762 (2024)